Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

2.

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM.

Br J Cancer. 2012 Jun 5;106(12):1967-75. doi: 10.1038/bjc.2012.207. Epub 2012 May 17.

3.

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.

Clin Cancer Res. 2007 Dec 1;13(23):7191-8.

4.

Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.

Stamelos VA, Robinson E, Redman CW, Richardson A.

Gynecol Oncol. 2013 Feb;128(2):377-82. doi: 10.1016/j.ygyno.2012.11.019. Epub 2012 Nov 17.

PMID:
23168176
5.

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.

Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord AA.

Gynecol Oncol. 2011 Apr;121(1):187-92. doi: 10.1016/j.ygyno.2010.11.017. Epub 2011 Jan 3.

6.

HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.

Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al-Kuraya KS.

Lab Invest. 2011 Jan;91(1):124-37. doi: 10.1038/labinvest.2010.136. Epub 2010 Jul 26.

7.

CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.

Deying W, Feng G, Shumei L, Hui Z, Ming L, Hongqing W.

Biosci Rep. 2017 Apr 10;37(2). pii: BSR20160470. doi: 10.1042/BSR20160470. Print 2017 Apr 28.

8.

Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.

Kwon Y, Smith BD, Zhou Y, Kaufman MD, Godwin AK.

Oncogene. 2015 Jan 8;34(2):144-53. doi: 10.1038/onc.2013.539. Epub 2013 Dec 23.

9.

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.

Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L.

Drug Des Devel Ther. 2015 Aug 26;9:4897-907. doi: 10.2147/DDDT.S85837. eCollection 2015.

11.

Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.

Weigel MT, Rath K, Alkatout I, Wenners AS, Schem C, Maass N, Jonat W, Mundhenke C.

Oncology. 2014;87(4):232-45. doi: 10.1159/000363656. Epub 2014 Aug 8.

PMID:
25116401
12.

PTEN reconstitution alters glioma responses to c-Met pathway inhibition.

Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J.

Anticancer Drugs. 2011 Oct;22(9):905-12. doi: 10.1097/CAD.0b013e3283484750.

13.

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM.

Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26.

14.

The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.

Jain HV, Meyer-Hermann M.

Cancer Res. 2011 Feb 1;71(3):705-15. doi: 10.1158/0008-5472.CAN-10-3174. Epub 2010 Dec 17.

15.

Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.

Chattopadhyay C, Grimm EA, Woodman SE.

PLoS One. 2014 Feb 13;9(2):e83957. doi: 10.1371/journal.pone.0083957. eCollection 2014.

16.

Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.

Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K, Mohri Y, Inoue Y, Goel A, Kusunoki M.

Int J Cancer. 2012 Jun 15;130(12):2912-21. doi: 10.1002/ijc.26330. Epub 2011 Sep 12.

17.

HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM.

Clin Cancer Res. 2009 Jun 1;15(11):3740-50. doi: 10.1158/1078-0432.CCR-08-3252. Epub 2009 May 26.

18.

Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.

Kalogera E, Roy D, Khurana A, Mondal S, Weaver AL, He X, Dowdy SC, Shridhar V.

Gynecol Oncol. 2017 Jul;146(1):187-195. doi: 10.1016/j.ygyno.2017.04.022. Epub 2017 May 22.

PMID:
28545688
19.

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ.

J Natl Cancer Inst. 2004 May 19;96(10):739-49.

PMID:
15150302
20.

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM.

Gynecol Oncol. 2013 Oct;131(1):207-12. doi: 10.1016/j.ygyno.2013.07.088. Epub 2013 Jul 20.

PMID:
23877012

Supplemental Content

Support Center